A new industry analysis focused on CDMO engagement timing argued that companies should involve contract development and manufacturing organizations early in development while keeping key CMC decisions flexible. The report described how front-loading formulation work based on preliminary targets can force expensive rework when PK and tox results shift early assumptions. The piece emphasizes that clinical, nonclinical, and CMC workstreams are tightly coupled—dose, formulation, route, and nonclinical package requirements can influence the eventual manufacturing strategy. For biotech teams preparing for IND-enabling timelines, the guidance frames early CDMO engagement as a coordination tool rather than a mandate to lock specifications before evidence is available.